Topical macrolide immunomodulators. A role in the treatment of vitiligo?
| Autor: | Marie-Jeanne P. Gerritsen, M. Tjioe, W.H.P.M. Vissers |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Chronic inflammation and autoimmunity [UMCN 4.2]
medicine.medical_specialty integumentary system business.industry Pharmacology toxicology Calcineurin Inhibitors Vitiligo Dermatology General Medicine Atopic dermatitis medicine.disease Administration Cutaneous Tacrolimus Pharmacotherapy Psoriasis Immunology medicine Humans Macrolides business skin and connective tissue diseases Immunosuppressive Agents |
| Zdroj: | American Journal of Clinical Dermatology, 7, 7-12 American Journal of Clinical Dermatology, 7, 1, pp. 7-12 American Journal of Clinical Dermatology, 6, 1-6 American Journal of Clinical Dermatology, 6, 1, pp. 1-6 |
| ISSN: | 1175-0561 |
| Popis: | Item does not contain fulltext Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases, such as psoriasis, lichen planus, and even vitiligo, is expanding rapidly. It is generally accepted that autoimmune factors play an important role in vitiligo. In this article, the possible use and mechanism of topical macrolide immunomodulators in the treatment of vitiligo are discussed, together with the current state of clinical studies and case reports. These limited reports indicate that topical macrolide immunomodulators may play a role in the treatment of vitiligo, particularly in areas where use of potent corticosteroids is contraindicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink